Glioma Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024

DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Glioma @ Glioma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Glioma Pipeline Report

* In September 2024:- Day One Biopharmaceuticals Inc- This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
* In September 2024:- Chimerix- This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
* DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.
* The leading Glioma Companies working in the market include BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen , and others.
* Promising Glioma Therapies in the various stages of development include DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103 , and others.

Learn more about Glioma in clinical trials @ Glioma Treatment Drugs [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glioma Disease Emerging Drugs

* ONC 201: Chimerix
* Marizomib: Bristol-Myers Squibb
* MDNA55: Medicenna Therapeutics, Inc.
* CAN-3110: Candel Therapeutics

Glioma Therapeutics Assessment

There are approx. 180+ Glioma companies which are developing the Glioma therapies. The Glioma Companies which have their Glioma Disease drug candidates in the most advanced stage, i.e. Phase III include, Chimerix.

DelveInsight's Glioma Pipeline Report covers around 200+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Glioma in development @ Glioma Clinical Trials [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glioma Companies

BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.

The Glioma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Glioma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

To know more about Glioma, visit @ Glioma Therapeutics Segmentation [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Glioma Pipeline Report

* Coverage- Global
* Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Glioma Companies- BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.
* Glioma Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.

For further information on the Glioma Pipeline Therapeutics, reach out @ Glioma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Glioma Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Glioma Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ONC 201: Chimerix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Safusidenib: AnHeart Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CAN-3110: Candel Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Glioma Disease Key Companies
* Glioma Disease Key Products
* Glioma Disease- Unmet Needs
* Glioma Disease- Market Drivers and Barriers
* Glioma Disease- Future Perspectives and Conclusion
* Glioma Disease Analyst Views
* Glioma Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioma-treatment-drugs-clinical-trials-pipeline-insights-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.